Most content about Mounjaro skews toward weight loss — but glycemic control is its actual FDA-approved indication. Here's the dosing and trial data for that use.
Mounjaro is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes — the trial program supporting that approval showed A1C reductions of roughly 2.0% to 2.3% depending on dose.
Per FDA prescribing information for tirzepatide (Mounjaro) and the SURPASS clinical trial program, Eli Lilly. Not medical advice.
The same titration schedule applies whether Mounjaro is prescribed for diabetes or, under the Zepbound brand, for weight management. Your prescriber determines the target maintenance dose based on your response and tolerability.
In SURPASS-2, tirzepatide reduced A1C by 2.01% to 2.30% depending on dose over 40 weeks, all three doses outperforming semaglutide 1mg's 1.86%.
Trial participants with diabetes also saw meaningful weight loss, though typically less than in trials of people without diabetes.
Trials studied tirzepatide added to metformin and other diabetes medications, not as a first-line standalone treatment for everyone.
One email at launch · free trial · no credit card